A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma

Summary

This is a Phase 1/2 study of imvotamab in adult subjects with relapsed or refractory B-cell Non-Hodgkin Lymphoma. This study will consist of a dose-escalation stage, a combination stage, and a randomized dose-expansion stage where subjects will be enrolled into indication-specific expansion cohorts. imvotamab will be administered intravenously (IV). Additional CD20-positive NHL histologies (e.g. MZL and MCL), may be allowed with Medical Monitor approval during the Dose-Escalation Phase of the study.

Timeline

Start

2019-09-30

Primary completion

2024-02-16

Completion

2024-02-22

Outcome

Outcome not reported

Stopped (Business): “Strategic Pipeline Prioritization: Clinical development of imvotamab in autoimmune diseases prioritized.”

Drugs

Indications